ABCB1 activity did not directly mediate chemotherapy resistance, and ABCB1 inhibition did not improve the outcome of AML patients with overexpressed ABCB1, but this result may be useful in clinical routine for improving the chemotherapy selection [28]. The gene discussed is ABCB1; the disease is acute myeloid leukemia.